Global Patent Index - EP 1680116 A1

EP 1680116 A1 20060719 - COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS

Title (en)

COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS

Title (de)

KOMBINATIONSBEHANDLUNG VON ADIPOSITAS MIT SELEKTIVEN CB1-ANTAGONISTEN UND LIPASEHEMMERN

Title (fr)

TRAITEMENT COMBINE DE L'OBESITE CONTENANT DES ANTAGONISTES SELECTIVES DE CB1 ET DES INHIBITEURS DE LIPASE

Publication

EP 1680116 A1 20060719 (EN)

Application

EP 04791298 A 20041022

Priority

  • EP 2004052643 W 20041022
  • EP 03103962 A 20031024
  • US 51399603 P 20031027
  • EP 04791298 A 20041022

Abstract (en)

[origin: WO2005039579A1] The present invention relates to a novel medical use of selective CB1 receptor antagonistic compounds in combination with lipase inhibitors. Said compounds are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The CB1 receptor antagonistic compounds suitable according to the invention are elucidated in more detail in the description. Preferred lipase inhibitors are orlistat, panclicins, ATL-962 and/or lipstatin.

IPC 1-7

A61K 31/454; A61K 31/5355; A61K 31/343; A61K 31/05; A61K 31/352; A61K 31/353; A61K 31/16; A61K 31/165; A61K 31/4164; A61K 31/397; A61K 31/4965; A61K 31/497; A61K 31/4166; A61K 31/365; A61K 31/785

IPC 8 full level

A61K 31/05 (2006.01); A61K 31/16 (2006.01); A61K 31/165 (2006.01); A61K 31/343 (2006.01); A61K 31/352 (2006.01); A61K 31/353 (2006.01); A61K 31/365 (2006.01); A61K 31/397 (2006.01); A61K 31/4164 (2006.01); A61K 31/4166 (2006.01); A61K 31/454 (2006.01); A61K 31/4965 (2006.01); A61K 31/497 (2006.01); A61K 31/5355 (2006.01); A61K 31/785 (2006.01); A61K 45/06 (2006.01)

CPC (source: EP)

A61K 31/05 (2013.01); A61K 31/16 (2013.01); A61K 31/165 (2013.01); A61K 31/343 (2013.01); A61K 31/352 (2013.01); A61K 31/353 (2013.01); A61K 31/365 (2013.01); A61K 31/397 (2013.01); A61K 31/4164 (2013.01); A61K 31/4166 (2013.01); A61K 31/454 (2013.01); A61K 31/4965 (2013.01); A61K 31/497 (2013.01); A61K 31/5355 (2013.01); A61K 31/785 (2013.01); A61K 45/06 (2013.01)

C-Set (source: EP)

  1. A61K 31/05 + A61K 2300/00
  2. A61K 31/4166 + A61K 2300/00
  3. A61K 31/454 + A61K 2300/00
  4. A61K 31/4965 + A61K 2300/00
  5. A61K 31/497 + A61K 2300/00
  6. A61K 31/5355 + A61K 2300/00
  7. A61K 31/785 + A61K 2300/00
  8. A61K 31/16 + A61K 2300/00
  9. A61K 31/165 + A61K 2300/00
  10. A61K 31/343 + A61K 2300/00
  11. A61K 31/352 + A61K 2300/00
  12. A61K 31/353 + A61K 2300/00
  13. A61K 31/365 + A61K 2300/00
  14. A61K 31/397 + A61K 2300/00
  15. A61K 31/4164 + A61K 2300/00

Citation (search report)

See references of WO 2005039579A1

Citation (examination)

  • MOLNÁR D.: "New drug policy in childhood obesity", INT. J. OBES., vol. 29, 2005, pages S62 - S65
  • LANGGUTH P. ET AL.: "Biopharmazie", 2004, WILEY-VCH VERLAG GMBH & CO. KGAA
  • http://www.dge.de/modules.php?name=News&file=print&sid=680

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2005039579 A1 20050506; CA 2543197 A1 20050506; CN 1867332 A 20061122; EP 1680116 A1 20060719; RU 2006117637 A 20071210

DOCDB simple family (application)

EP 2004052643 W 20041022; CA 2543197 A 20041022; CN 200480030088 A 20041022; EP 04791298 A 20041022; RU 2006117637 A 20041022